You are here: Industry Insights > Diabetes

News List

AnTolRx Announces Pfizer Exercises Option To License Immune Tolerance Therapy For Potential Treatment Of Type 1 Diabetes pharmafocusasia
March 07, 2019
AnTolRx, Inc., a private biotechnology company and a leader in immune tolerance, today announced that Pfizer Inc has exercised the option granted under a June 2016 agreement to license an immune...
Statins might be linked to increased risk of diabetes europeanpharmaceuticalreview
March 07, 2019
Researchers have identified a possible association between use of statins and developing type 2 diabetes after following patients for 15 years…
Sanofi, boosted by partnerships, lays out connected tech ambitions in diabetes fiercepharma
March 07, 2019
Technology solutions are key to the future of diabetes—especially personalized, "smart" connected tech.
Diabetes coverage is improving, but could a shake-up be on the way with Novo’s oral semaglutide? fiercepharma
March 06, 2019
Payer pressure has been squeezing diabetes drugs, leading to some major sales difficulties and layoff rounds. As Bernstein analyst Wimal Kapadia observes, things are on the mend in terms of 2019 formulary coverage, but one drug could “disrupt them all.”
Lilly to Introduce Lower-Priced Insulin americanpharmaceuticalreview
March 06, 2019
Eli Lilly and Company announced the company will introduce a lower-priced version of Humalog® (insulin lispro injection 100 units/mL) in the United States, providing people with diabetes an insulin option that will have a list price 50 percent lower than
Ozempic® superior in lowering blood sugar and weight vs placebo, both in combination with SGLT-2 inhibitors worldpharmanews
March 06, 2019
Novo Nordisk announced publication of results from the SUSTAIN 9 Phase 3b trial in The Lancet Diabetes & Endocrinology.
Ozempic® superior in lowering blood sugar and weight vs placebo, both in combination with SGLT-2 inhibitors worldpharmanews
March 06, 2019
Novo Nordisk announced publication of results from the SUSTAIN 9 Phase 3b trial in The Lancet Diabetes & Endocrinology.
UCSF discover potential new treatment approach for type 1 diabetes pharmaceutical-technology
February 26, 2019
Researchers at the University of California, San Francisco (UCSF) Diabetes Centre have uncovered evidence to suggest assumptions about the cause of type 1 diabetes are incorrect.....
AstraZeneca announces its Brilinta reduced MACE in CAD and type 2 diabetes patients pharmaceutical-technology
February 26, 2019
Global pharmaceutical company AstraZeneca has announced its drug Brilinta (ticagrelor) in combination with aspirin has met its primary endpoint, a statistically significant reduction in major adverse cardiovascular events, in the Phase III THEMIS trial...
Abbott and Novo Nordisk enter partnership to provide integrated digital solution to people with diabetes using insulin worldpharmanews
February 21, 2019
Abbott and Novo Nordisk today announced a non-exclusive partnership that will integrate insulin dose data from Novo Nordisk...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 37 38 Next page